文献速递细菌感染、耐药与抗菌药物医院感染防控

COVID-19相关医疗变化对苏格兰临床大肠埃希菌耐药性的影响:中断时间序列分析

Impact of COVID-19-related healthcare changes on antibiotic resistance in clinical Escherichia coli isolates: interrupted time series analyses in Scotland, UK.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

该研究分析苏格兰约49万人2018年1月至2022年3月数据,用Joinpoint回归识别2020年1月为干预点,中断时间序列分析评估COVID-19相关医疗利用和抗生素处方变化对大肠埃希菌血液和尿液分离株耐药及多重耐药(MDR)比例的影响。结果显示尿液分离株中耐药(非MDR)比例水平变化+2.5%(95%CI -0.4%至5.4%)、趋势+0.3%/月(95%CI 0.1%至0.5%),MDR水平变化+0.4%(95%CI -2.0%至2.8%)、趋势-0.3%/月(95%CI -0.5%至-0.1%);至干预后9个月,耐药(非MDR)比例较无干预预测值升高而MDR比例降低,血培养分离株有类似变化但不确定性更大。结论认为COVID-19相关医疗和抗生素使用变化导致MDR大肠埃希菌小幅但显著减少。

要点

  • 2020年1月为干预点,尿液大肠埃希菌耐药(非MDR)比例趋势每月增加0.3%。
  • 尿液MDR大肠埃希菌比例趋势每月下降0.3%,干预后9个月低于预测水平。
  • 血培养分离株变化类似但估计不确定性较大。

核心结论

  • COVID-19相关医疗和抗生素使用变化导致多重耐药大肠埃希菌小幅但显著减少。

研究设计与样本

  • 基于苏格兰约49万人2018年1月至2022年3月数据的中断时间序列分析。
  • 用Joinpoint回归识别医疗就诊和抗生素使用趋势变化点作为干预时间点。

主要发现

  • 尿液大肠埃希菌耐药(非MDR)比例干预前为26%,水平变化+2.5%(95%CI -0.4%至5.4%),趋势+0.3%/月(95%CI 0.1%至0.5%)。
  • 尿液MDR大肠埃希菌比例干预前为35%,水平变化+0.4%(95%CI -2.0%至2.8%),趋势-0.3%/月(95%CI -0.5%至-0.1%)。
  • 至干预后9个月,耐药(非MDR)比例较无干预预测值升高,MDR比例降低。
  • 血培养分离株有类似变化,但估计不确定性较大。

临床怎么用

  • 研究结果支持抗菌药物管理和感染控制干预措施的制定与评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The COVID-19 pandemic impacted healthcare use, with mixed reports regarding impacts on antimicrobial resistance. The aim was to identify changes in healthcare utilisation and antibiotic prescribing related to the COVID-19 pandemic and quantify subsequent impacts on antibiotic resistance in clinical Escherichia coli isolates in Scotland. METHODS: Data involving ∼490 000 people from January 2018 to March 2022 were analysed. Joinpoint regression analyses identified trend changes in healthcare encounters, and antibiotic use in community and hospital settings. Using these joinpoints as an 'intervention' timepoint, interrupted time series analysis quantified associated changes in proportions of E. coli blood and urine culture isolates that were antibiotic resistant and multidrug resistant (MDR). RESULTS: January 2020 was identified as the intervention point. From 26% resistant (not MDR) and 35% MDR among urine E. coli isolates immediately pre-intervention, there were changes in level of +2.5% (95%CI -0.4% to 5.4%) and trend of +0.3% (95%CI 0.1% to 0.5%) per month for resistant (not MDR), and level change of +0.4% (95%CI -2.0% to 2.8%) but trend change of -0.3% (95%CI -0.5% to -0.1%) per month for MDR. By 9 month post-intervention, compared with predicted levels without intervention, resistant (not MDR) proportions increased while MDR proportions decreased. Similar changes occurred among blood culture isolates, but with less certainty around estimates. CONCLUSION: Small but significant reductions in MDR E. coli resulted from COVID-19-related changes in healthcare and antibiotic use. The findings are critical for antimicrobial stewardship and infection control interventions and evaluation.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Ciaccio L, Donnan PT, Parcell BJ, et al. Impact of COVID-19-related healthcare changes on antibiotic resistance in clinical Escherichia coli isolates: interrupted time series analyses in Scotland, UK. J Antimicrob Chemother. 2026. PMID: 41700716. doi:10.1093/jac/dkag049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。